Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DB107-RRV and DB107-FC in Newly Diagnosed High Grade Glioma
NCT06504381Phase 2Recruiting
- Sponsor
- University of California, San Francisco
- Start
- Jan 2025
- Primary completion
- Jan 2028
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of vocimagene amiretrorepvec in high-grade glioma (HGG), sponsored by University of California, San Francisco. Started Jan 2025; status: recruiting.
02
Drugs
vocimagene amiretrorepvec
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT06504381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06504381.